Core Viewpoint - The company Huaren Health (301408.SZ) announced that its wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration [1] Group 1: Product Information - Fumaric Acid Vonoprazan Tablets are a new type of potassium ion competitive acid blocker (P-CAB) [1] - The drug can reversibly inhibit the H+/K+-ATPase on gastric parietal cells in a potassium ion competitive manner without relying on an acidic environment [1] - It is stable in highly acidic environments and can rapidly, effectively, and durably suppress gastric acid secretion from gastric parietal cells, significantly reducing the occurrence of nighttime gastric acid elevation [1]

Core Viewpoint - Huaren Health (301408.SZ) has received the acceptance notice for the drug registration application of Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration, indicating a significant step towards market entry for this new medication [1] Group 1: Product Information - Fumaric Acid Vonoprazan Tablets are a new type of potassium-competitive acid blocker (P-CAB) that can reversibly inhibit the H+/K+-ATPase in gastric parietal cells without relying on an acidic environment [1] - The drug is stable in highly acidic environments and can rapidly, effectively, and durably suppress gastric acid secretion, significantly reducing the occurrence of nighttime acid elevation [1] - As a next-generation acid suppressant, it offers a unique mechanism for acid secretion inhibition, leading to better therapeutic effects and higher safety [1] Group 2: Usage Guidelines - The use of Fumaric Acid Vonoprazan Tablets must strictly follow medical advice to ensure rational medication [1]